Promising therapies in multiple myeloma

Por Bianchi, Giada, Richardson, Paul G., Anderson, Kenneth C.
Publicado no Blood (2015)

Bortezomib in the treatment of multiple myeloma

Por Ghobrial, Irene M., Richardson, Paul G., Anderson, Kenneth C.
Publicado em 2011

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

Por Hideshima, Teru, Raje, Noopur, Richardson, Paul G, Anderson, Kenneth C
Publicado em 2008

From the bench to the bedside: emerging new treatments in multiple myeloma

Por Mitsiades, Constantine S., Hayden, Patrick J., Anderson, Kenneth C., Richardson, Paul G.
Publicado em 2007

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy

Por Voorhees, Peter M., Laubach, Jacob, Anderson, Kenneth C., Richardson, Paul G.
Publicado no Blood (2013)

Kidney Disease and Multiple Myeloma

Por Heher, Eliot C., Rennke, Helmut G., Laubach, Jacob P., Richardson, Paul G.
Publicado em 2013

Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

Por Richardson, Paul G, Eng, Cathy, Kolesar, Jill, Hideshima, Teru, Anderson, Kenneth C
Publicado no Expert Opin Drug Metab Toxicol (2012)

Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethason...

Por Saboo, Sachin S., Fennessy, Fiona, Benajiba, Lina, Laubach, Jacob, Anderson, Kenneth C., Richardson, Paul G.
Publicado no J Clin Oncol (2012)

Emerging therapies for multiple myeloma

Por Podar, Klaus, Tai, Yu-Tzu, Hideshima, Teru, Vallet, Sonia, Richardson, Paul G, Anderson, Kenneth C
Publicado em 2009

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

Por Chauhan, Dharminder, Singh, Ajita V., Ciccarelli, Bryan, Richardson, Paul G., Palladino, Michael A., Anderson, Kenneth C.
Publicado em 2010

How I treat plasma cell leukemia

Por van de Donk, Niels W. C. J., Lokhorst, Henk M., Anderson, Kenneth C., Richardson, Paul G.
Publicado em 2012

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors

Por Cea, Michele, Cagnetta, Antonia, Gobbi, Marco, Patrone, Franco, Richardson, Paul G., Hideshima, Teru, Anderson, Kenneth C.
Publicado em 2013

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

Por LAUBACH, JACOB P., MITSIADES, CONSTANTINE S., ROCCARO, ALDO M., GHOBRIAL, IRENE M., ANDERSON, KENNETH C., RICHARDSON, PAUL G.
Publicado em 2009

Induction of differential apoptotic pathways in multiple myeloma cells by class selective histone deacetylase inhibitors

Por Hideshima, Teru, Mazitschek, Ralph, Santo, Loredana, Mimura, Naoya, Gorgun, Gullu, Richardson, Paul G., Raje, Noopur, Anderson, Kenneth C.
Publicado no Leukemia (2013)

Proteasome inhibitors in multiple myeloma: 10 years later

Por Moreau, Philippe, Richardson, Paul G., Cavo, Michele, Orlowski, Robert Z., San Miguel, Jesús F., Palumbo, Antonio, Harousseau, Jean-Luc
Publicado em 2012

Synthetic lethal approaches exploiting DNA damage in aggressive myeloma

Por Cottini, Francesca, Hideshima, Teru, Suzuki, Rikio, Tai, Yu-Tzu, Bianchini, Giampaolo, Richardson, Paul G., Anderson, Kenneth C., Tonon, Giovanni
Publicado no Cancer Discov (2015)

A Novel Alkylating Agent Melflufen Induces Irreversible DNA Damage and Cytotoxicity in Multiple Myeloma Cells

Por Ray, Arghya, Das, Deepika Sharma, Song, Yan, Nordström, Eva, Gullbo, Joachim, Richardson, Paul G., Chauhan, Dharminder, Anderson, Kenneth C.
Publicado no Br J Haematol (2016)

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study

Por Richardson, Paul G., Chanan-Khan, Asher A., Alsina, Melissa, Albitar, Maher, Berman, David, Messina, Marianne, Mitsiades, Constantine S., Anderson, Kenneth C.
Publicado em 2010

Kidney disease associated with plasma cell dyscrasias

Por Heher, Eliot C., Goes, Nelson B., Spitzer, Thomas R., Raje, Noopur S., Humphreys, Benjamin D., Anderson, Kenneth C., Richardson, Paul G.
Publicado em 2010

The challenge of cross-trial comparisons using limited data

Por Laubach, Jacob P., Faber, Edward A., Voorhees, Peter, Moslehi, Javid, Varga, Cindy, Niculescu, Liviu, Anderson, Kenneth C., Richardson, Paul G.
Publicado em 2014